Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $62.00 price target on the stock.
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its price target lowered by analysts at Citigroup Inc. from $62.00 to $60.00. They now have a "buy" rating on the stock.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus [Yahoo! Finance]
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its price target lowered by analysts at Wedbush from $51.00 to $50.00. They now have an "outperform" rating on the stock.